These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35279856)

  • 1. The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry.
    Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
    Contact Dermatitis; 2022 Aug; 87(2):185-191. PubMed ID: 35279856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry.
    Kamphuis E; Loman L; Han HL; Romeijn GLE; Politiek K; Schuttelaar MLA
    Contact Dermatitis; 2023 May; 88(5):351-362. PubMed ID: 36621910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.
    Oosterhaven JAF; Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
    J Dermatol; 2019 Aug; 46(8):680-685. PubMed ID: 31187925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
    Voorberg AN; Kamphuis E; Christoffers WA; Schuttelaar MLA
    Br J Dermatol; 2023 Sep; 189(4):400-409. PubMed ID: 37170922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up.
    Navarro-Triviño FJ; Galán-Gutiérrez M; Hita JC; Ruiz-Villaverde R; Domínguez-Cruz J; Pereyra-Rodríguez JJ
    Dermatitis; 2024; 35(S1):S55-S61. PubMed ID: 37883648
    [No Abstract]   [Full Text] [Related]  

  • 6. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
    Oosterhaven JAF; Spekhorst LS; Zhang J; Voorberg AN; Romeijn GLE; Boesjes CM; de Graaf M; de Bruin-Weller MS; Schuttelaar MLA
    J Dermatolog Treat; 2022 Jun; 33(4):1986-1989. PubMed ID: 34151695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials.
    Simpson EL; Rahawi K; Hu X; Chu AD; Nduaka C; Jazayeri S; Lio P; Lynde C; Schuttelaar MLA
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1863-1870. PubMed ID: 37184290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
    Spekhorst LS; de Graaf M; Zuithoff NPA; van den Reek JMPA; Kamsteeg M; Boesjes CM; Romeijn GLE; Loman L; Haeck I; Oosting AJ; de Boer-Brand A; Touwslager WRH; Flinterman A; van Lynden-van Nes AMT; Gostynski AH; de Bruin-Weller MS; Schuttelaar ML
    JAMA Dermatol; 2022 Sep; 158(9):1048-1056. PubMed ID: 35947364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
    Ariëns LFM; van der Schaft J; Spekhorst LS; Bakker DS; Romeijn GLE; Kouwenhoven TA; Kamsteeg M; Voorberg AN; Oosting AJ; de Ridder I; Sloeserwij A; Haeck I; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    J Am Acad Dermatol; 2021 Apr; 84(4):1000-1009. PubMed ID: 32946967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry.
    Spekhorst LS; de Graaf M; Loeff F; Zuithoff NPA; Bakker D; Boesjes CM; Thijs J; Achten R; van Wijk F; Rispens T; de Bruin-Weller MS
    JAMA Dermatol; 2022 Dec; 158(12):1409-1413. PubMed ID: 36322072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
    Kamphuis E; Boesjes CM; Loman L; Kamsteeg M; Haeck I; Van Lynden-van Nes AMT; Politiek K; Van der Gang LF; De Graaf M; De Bruin-Weller MS; Schuttelaar MLA
    Acta Derm Venereol; 2024 Feb; 104():adv19454. PubMed ID: 38323500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
    Zhang J; Boesjes CM; Loman L; Kamphuis E; Romeijn MLE; Spekhorst LS; Haeck I; van der Gang LF; Dekkers CC; van der Rijst LP; Oosting AJ; van Lumig P; van Lynden-van Nes AMT; Tupker RA; Nijssen A; Flinterman A; Politiek K; Touwslager WRH; Christoffers WA; Stewart SM; Kamsteeg M; de Graaf M; de Bruin-Weller MS; Schuttelaar MA
    J Am Acad Dermatol; 2024 Aug; 91(2):300-311. PubMed ID: 38653344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
    Simpson EL; Silverberg JI; Worm M; Honari G; Masuda K; Syguła E; Schuttelaar MLA; Mortensen E; Laws E; Akinlade B; Patel N; Maloney J; Paleczny H; Delevry D; Xiao J; Dubost-Brama A; Bansal A
    J Am Acad Dermatol; 2024 Jun; 90(6):1190-1199. PubMed ID: 38296199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
    Ariëns LFM; Bakker DS; Spekhorst LS; Van der Schaft J; Thijs JL; Haeck I; Flinterman AE; Kamsteeg M; Schuttelaar MLA; De Bruin-Weller MS
    Acta Derm Venereol; 2021 Oct; 101(10):adv00573. PubMed ID: 34396421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.